File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: AFM analysis of the multiple types of molecular interactions involved in rituximab lymphoma therapy on patient tumor cells and NK cells

TitleAFM analysis of the multiple types of molecular interactions involved in rituximab lymphoma therapy on patient tumor cells and NK cells
Authors
KeywordsLymphoma
Fc receptor
Atomic force microscopy
Antibody-dependent cellular cytotoxicity
Natural killer cell
CD20
Issue Date2014
Citation
Cellular Immunology, 2014, v. 290, n. 2, p. 233-244 How to Cite?
Abstract© 2014. Rituximab is a monoclonal antibody drug approved for the treatment of patients with lymphomas. Rituximab's main killing mechanism is antibody-dependent cellular cytotoxicity (ADCC). During ADCC, rituximab's fragment antigen binding (Fab) region binds to the CD20 antigen on the tumor cell and its fragment crystallizable (Fc) region binds to the Fc receptor (FcR) on the natural killer (NK) cells. In this study, two types of molecular interactions (CD20-rituximab, FcR-rituximab) involved in ADCC were measured simultaneously on cells prepared from biopsy specimens of lymphoma patients by utilizing atomic force microscopy (AFM) with functionalized tips carrying rituximab. NK cells were detected by specific NKp46 fluorescent labeling and tumor cells were detected by specific ROR1 fluorescent labeling. Based on the fluorescence recognition, the binding affinity and distribution of FcRs on NK cells, and CD20 on tumor cells, were quantitatively measured and mapped. The binding affinity and distribution of FcRs (on NK cells) and CD20 (on tumor cells) were associated with rituximab clinical efficacy. The experimental results provide a new approach to simultaneously quantify the multiple types of molecular interactions involved in rituximab ADCC mechanism on patient biopsy cells, which is of potential clinical significance to predict rituximab efficacy for personalized medicine.
Persistent Identifierhttp://hdl.handle.net/10722/213430
ISSN
2015 Impact Factor: 2.399
2015 SCImago Journal Rankings: 1.020

 

DC FieldValueLanguage
dc.contributor.authorLi, Mi-
dc.contributor.authorXiao, Xiubin-
dc.contributor.authorZhang, Weijing-
dc.contributor.authorLiu, Lianqing-
dc.contributor.authorXi, Ning-
dc.contributor.authorWang, Yuechao-
dc.date.accessioned2015-07-28T04:07:15Z-
dc.date.available2015-07-28T04:07:15Z-
dc.date.issued2014-
dc.identifier.citationCellular Immunology, 2014, v. 290, n. 2, p. 233-244-
dc.identifier.issn0008-8749-
dc.identifier.urihttp://hdl.handle.net/10722/213430-
dc.description.abstract© 2014. Rituximab is a monoclonal antibody drug approved for the treatment of patients with lymphomas. Rituximab's main killing mechanism is antibody-dependent cellular cytotoxicity (ADCC). During ADCC, rituximab's fragment antigen binding (Fab) region binds to the CD20 antigen on the tumor cell and its fragment crystallizable (Fc) region binds to the Fc receptor (FcR) on the natural killer (NK) cells. In this study, two types of molecular interactions (CD20-rituximab, FcR-rituximab) involved in ADCC were measured simultaneously on cells prepared from biopsy specimens of lymphoma patients by utilizing atomic force microscopy (AFM) with functionalized tips carrying rituximab. NK cells were detected by specific NKp46 fluorescent labeling and tumor cells were detected by specific ROR1 fluorescent labeling. Based on the fluorescence recognition, the binding affinity and distribution of FcRs on NK cells, and CD20 on tumor cells, were quantitatively measured and mapped. The binding affinity and distribution of FcRs (on NK cells) and CD20 (on tumor cells) were associated with rituximab clinical efficacy. The experimental results provide a new approach to simultaneously quantify the multiple types of molecular interactions involved in rituximab ADCC mechanism on patient biopsy cells, which is of potential clinical significance to predict rituximab efficacy for personalized medicine.-
dc.languageeng-
dc.relation.ispartofCellular Immunology-
dc.subjectLymphoma-
dc.subjectFc receptor-
dc.subjectAtomic force microscopy-
dc.subjectAntibody-dependent cellular cytotoxicity-
dc.subjectNatural killer cell-
dc.subjectCD20-
dc.titleAFM analysis of the multiple types of molecular interactions involved in rituximab lymphoma therapy on patient tumor cells and NK cells-
dc.typeArticle-
dc.description.natureLink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.cellimm.2014.07.003-
dc.identifier.pmid25117605-
dc.identifier.scopuseid_2-s2.0-84907089061-
dc.identifier.volume290-
dc.identifier.issue2-
dc.identifier.spage233-
dc.identifier.epage244-
dc.identifier.eissn1090-2163-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats